TARA News and Press, ArTara Therapeutics Inc. From 06/10/21

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Boa...

Protara Therapeutics (TARA) has surged in early hours with a gain of ~6.1% as H.C. Wainwright analyst Andrew S. Fein initiates the coverage with a buy rating and a price target of $40.00 implying a premium of ~332.0% to the previous close.Protara’s lead asset, TARA-002 is cur...

Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories N.V. (CLB) +...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming vi...

ArTara Therapeutics (TARA): Q1 GAAP EPS of -$1.20 misses by $0.47.Cash, cash equivalents and investment of $155M.Press Release For further details see: ArTara Therapeutics EPS misses by $0.47

- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with FDA and Initiate Clinical Study of TARA-002 in Lymphatic Malformations - ...

Gainers: Sypris Solutions (SYPR) +75%.Ocugen (OCGN) +41%.Brooklyn ImmunoTherapeutics (BTX) +34%.MicroVision (MVIS) +32%.BioVie (BIVI) +29%.FreightCar America (RAIL) +27%.Uxin (UXIN) +26%.Birks Group (BGI) +24%.Meridian Bancorp (EBSB) +21%.22nd Century (XXII) +20%.Losers: I...

Following feedback from the FDA, Protara Therapeutics (TARA) will complete a confirmatory, large-scale, GMP manufacturing comparability study in 2H 2021 for TARA-002 for Lymphatic Malformations ("LMs").Following this study, the company anticipates moving the asset into phase 3.TARA-002 is der...

NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatme...